NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma

详细信息    查看全文

• 作者：Ying-hua He^a ; ^b ; ^c ; ^d ; Ming-fang Li^a ; ^b ; ^c ; ^d ; Xing-yan Zhang^a ; ^b ; ^c ; ^d ; Xiao-ming Meng^a ; ^b ; ^c ; ^d ; Cheng Huang^a ; ^b ; ^c ; ^d ; Jun Li^a ; ^b ; ^c ; ^d ; ^{lj@ahmu.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; ^{anyidaheyinghua@163.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：NLRC5 ; VEGF-A ; HCC ; PI3K/AKT signaling pathway
• 刊名：Toxicology
• 出版年：2016
• 出版时间：1 June 2016
• 年：2016
• 卷：359-360
• 期：Complete
• 页码：47-57
• 全文大小：2824 K

文摘

NLRC5, a newly found member of the NLR family and the largest member of nucleotide-binding, has been reported to regulate immune responses and is associated with hepatocellular carcinoma (HCC). We investigated the mechanisms and signaling pathways of NLRC5 in HCC progression. Increased expression of NLRC5, vascular endothelial growth factor-A (VEGF-A) were found in human HCC tissue. There was a positive correlation between NLRC5 and VEGF-A expression and cell proliferation were enhanced in NLRC5-overexpressing HepG2 cells, but inhibited in cells with NLRC5 silencing treatment. Interestingly, we found that up-regulation of NLRC5 also coordinated the activation of PI3K/AKT signaling pathway. An AKT inhibitor LY294002 blocked VEGF-A expression and AKT phosphorylation in HepG2 cells and NLRC5-overexpressing HepG2 cells. These results demonstrate that NLRC5 promotes HCC progression via the AKT/VEGF-A signaling pathway.